These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 890863)

  • 1. Synthesis of the nonatetracontapeptide corresponding to the sequence proposed for thymopoietin II.
    Fujino M; Shinagawa S; Fukuda T; Takaoki M; Kawaji H
    Chem Pharm Bull (Tokyo); 1977 Jun; 25(6):1486-9. PubMed ID: 890863
    [No Abstract]   [Full Text] [Related]  

  • 2. Synthesis of the nonatetracontapeptide corresponding to the entire amino acid sequence of thymopoietin III and its effect on the impaired T-lymphocyte transformation of a patient with common variable immunodeficiency.
    Abiko T; Shishido H; Sekino H
    Chem Pharm Bull (Tokyo); 1986 May; 34(5):2133-43. PubMed ID: 3488834
    [No Abstract]   [Full Text] [Related]  

  • 3. Synthesis of the octadecapeptide corresponding to positions 32 to 49 of the revised amino acid sequence of thymopoietin II and its effect on low E-rosette forming cells of an aged patient with chronic renal failure.
    Abiko T; Sekino H
    Chem Pharm Bull (Tokyo); 1982 Sep; 30(9):3271-7. PubMed ID: 7172335
    [No Abstract]   [Full Text] [Related]  

  • 4. Synthesis of the nonatetracontapeptide corresponding to the entire amino acid sequence of thymopoietin I and its effect on the low E-rosette-forming cells of a uremic patient.
    Abiko T; Sekino H
    Chem Pharm Bull (Tokyo); 1985 Apr; 33(4):1583-91. PubMed ID: 4042234
    [No Abstract]   [Full Text] [Related]  

  • 5. Syntheses and effects of human splenin (hSP) fragment 32-48 and an analog on the reduced B-lymphocytes of uremic patients.
    Abiko T; Sekino H
    Chem Pharm Bull (Tokyo); 1989 Sep; 37(9):2472-6. PubMed ID: 2605694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Syntheses and structure-activity relationships of thymopoietin.
    Abiko T
    Adv Exp Med Biol; 1987; 223():153-5. PubMed ID: 3447432
    [No Abstract]   [Full Text] [Related]  

  • 7. Biologically active analogs of thymopentin with enhanced enzymatic stability.
    Heavner GA; Kroon DJ; Audhya T; Goldstein G
    Peptides; 1986; 7(6):1015-9. PubMed ID: 3031628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection and quantitation of low levels of protected and unprotected (R)-amino acids in the synthesis of thymopentin, an immunoregulatory peptide.
    Cotter ML; Naldi R; Shaw C; Park S; Heavner GA
    J Pharm Sci; 1985 Apr; 74(4):489-91. PubMed ID: 3889276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of human thymopoietin (hTP) and examination of its immunological effect on the impaired blastogenic response of T-lymphocytes of uremic patients.
    Abiko T; Sekino H
    Chem Pharm Bull (Tokyo); 1988 Jul; 36(7):2506-16. PubMed ID: 3266475
    [No Abstract]   [Full Text] [Related]  

  • 10. Synthesis of [Glu34]human splenin (hSP) and examination of its immunological effect on the reduced B-lymphocytes of uremic patients.
    Abiko T; Sekino H
    Chem Pharm Bull (Tokyo); 1989 Feb; 37(2):391-6. PubMed ID: 2787213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural requirements for the biological activity of thymopentin analogs.
    Heavner GA; Audhya T; Kroon D; Goldstein G
    Arch Biochem Biophys; 1985 Oct; 242(1):248-55. PubMed ID: 2996431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and effects of two peptide fragments of thymopoietin II on E-rosette forming cells in the uremic state.
    Abiko T; Kumikawa M; Sekino H
    Chem Pharm Bull (Tokyo); 1979 Sep; 27(9):2233-7. PubMed ID: 519816
    [No Abstract]   [Full Text] [Related]  

  • 13. Immuno-regulating peptides, I. Synthesis and structure-activity relationships of thymopentin analogs.
    Kisfaludy L; Nyéki O; Schön I; Dénes L; Ember J; Szporny L; Hajós G; Szende B
    Hoppe Seylers Z Physiol Chem; 1983 Aug; 364(8):933-40. PubMed ID: 6629331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proton NMR investigation of Ln3+ complexes of thymopoietin 32-36.
    Vaughn JB; Stephens RL; Lenkinski RE; Krishna NR; Heavner GA; Goldstein G
    Biochim Biophys Acta; 1981 Nov; 671(1):50-60. PubMed ID: 7030403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Syntheses and effects of [Glu34]-thymopoietin II fragment 32-45 and its analogs on the impaired T-cell transformation in a patient with common variable immunodeficiency.
    Abiko T; Shishido H; Sekino H
    Biotechnol Appl Biochem; 1986; 8(2-3):160-71. PubMed ID: 3488750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Syntheses and effects of a thymopoietin II fragment and its analogs on the impaired T-cell transformation in a patient with common variable immunodeficiency.
    Abiko T; Shishido H; Sekino H
    J Appl Biochem; 1985 Dec; 7(6):408-22. PubMed ID: 3879489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of the revised amino acid sequence of thymopoietin II and examination of its immunological effect on the impaired T-lymphocyte transformation of a uremic patient with pneumonia.
    Abiko T; Sekino H
    Chem Pharm Bull (Tokyo); 1987 May; 35(5):2016-24. PubMed ID: 3499238
    [No Abstract]   [Full Text] [Related]  

  • 18. Synthesis of human splenin (hSP) and examination of its immunological effects on the impaired T- and B-lymphocytes in uremic patients.
    Abiko T; Sekino H
    Chem Pharm Bull (Tokyo); 1990 Feb; 38(2):487-91. PubMed ID: 2337963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation and complete amino acid sequence of human thymopoietin and splenin.
    Audhya T; Schlesinger DH; Goldstein G
    Proc Natl Acad Sci U S A; 1987 Jun; 84(11):3545-9. PubMed ID: 3473468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cooperativity of thymopoietin 32-36 (the active site) and thymopoietin 38-45 in receptor binding.
    Audhya T; Heavner GA; Kroon DJ; Goldstein G
    Regul Pept; 1984 Oct; 9(3):155-64. PubMed ID: 6098937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.